Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBITDA (2016 - 2025)

OptimizeRx's EBITDA history spans 16 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, EBITDA rose 123.93% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $6.8 million, up 123.93%, while the annual FY2024 figure was -$13.6 million, 48.31% up from the prior year.
  • EBITDA for Q3 2025 was $2.0 million at OptimizeRx, down from $3.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $3.6 million in Q4 2024 and bottomed at -$10.9 million in Q4 2023.
  • The 5-year median for EBITDA is -$3.6 million (2023), against an average of -$2.6 million.
  • The largest annual shift saw EBITDA plummeted 9937.28% in 2022 before it surged 185.06% in 2025.
  • A 5-year view of EBITDA shows it stood at $621080.0 in 2021, then plummeted by 239.17% to -$864348.0 in 2022, then crashed by 1161.41% to -$10.9 million in 2023, then skyrocketed by 133.33% to $3.6 million in 2024, then plummeted by 43.62% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's EBITDA are $2.0 million (Q3 2025), $3.2 million (Q2 2025), and -$2.1 million (Q1 2025).